AcelRx Pharma (ACRX) Completes $10M Common, Warrants Private Placement

June 4, 2012 7:35 AM EDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), completed its previously announced private placement of common stock and warrants to purchase common stock on June 1, 2012. Gross proceeds from the offering were approximately $10.0 million. Proceeds from the private placement are expected to be used for general corporate and working capital purposes, including the development of the ARX-01 Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Equity Offerings

Add Your Comment